Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
| MarketCap | 12.1B |
|---|---|
| PE Ratio | -3.1 |
| PEG Ratio | 0.7 |
| P/B | 1.1 |
| P/S (ttm) | 0.7 |
| Earning Growth (QoQ) | 12% |
| Revenue Growth (QoQ) | |
| Short % | 0% |
| Held by Institutions % | 53% |
| 1 Day Vol Adjusted Return | -1.4 |
| 1 Month Vol Adjusted Return | 3.3 |
| 3 Month Vol Adjusted Return | 1.2 |
| 6 Month Vol Adjusted Return | 1.7 |
| 20 Days SMA Price ZScore | 1.6 |
| 50 Days SMA Price ZScore | 1.2 |
| 12 -26 Days PPO | 0.9 |
| 1 Month Average Short Volume Ratio | 33.2 |
| 1 Day Volume Change ZScore | 0.5 |
| 1 Month Daily Vol | 2.5 |
Stock news
Teva Pharmaceutical Industries Ltd. (TEVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
When Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett speaks his mind, Wall Street and investors pay close attention. Since taking over at Berkshire Hathaway in the mid-1960s, Buffett has led his company's stock to an average annual return of 20% -- and this is without paying a penny in dividends. In aggregate, Berkshire Hathaway's stock is up more 2,800,000% in 56 years.
New York state and two of its counties want corporations held liable for the drug epidemic. One analyst thinks the case could push a global settlement.
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from clinical and real-world analyses examining the efficacy of AJOVY® (fremanezumab-vfrm) for the treatment of migraine, which is being presented at the American Headache Society (AHS) annual meeting, taking place virtually on June 3-6.
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that 11 presentations examining clinical and real-world data for AJOVY® (fremanezumab-vfrm) injection will be presented at the 2021 American Headache Society (AHS) Annual Meeting, taking place virtually June 3-6.
In this article we will take a look at the 10 best value stocks to invest in right now according to billionaire Abrams. You can skip our detailed analysis of Abrams’ history, investment philosophy, and hedge fund performance, and go directly to 5 Best Value Stocks to Invest in Right Now According to Billionaire David […]
Teva Announces the U.S. Launch of the First Generic Version of THIOLA® (tiopronin) tablets